HLA class II-restricted T cell receptors against mutated RAS
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsRami Yoseph, Paul F. Robbins, Steven A. Rosenberg
Life of this patent
Estimating the term…
Abstract
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Claims30
An isolated or purified T-cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class II molecule,
- wherein the mutated human RAS amino acid sequence is a mutated human Kirsten rat sarcoma viral oncogene homolog (KRAS), a mutated human Harvey rat sarcoma viral oncogene homolog (HRAS), or a mutated human Neuroblastoma rat sarcoma viral oncogene homolog (NRAS) amino acid sequence and the TCR comprises:
- an α chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1, an α chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2, an α chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 3, a β chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4, a β chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 5, and a β chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6.
An isolated or purified polypeptide comprising a functional portion of a TCR, wherein the functional portion comprises an α chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1, an α chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2, an α chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 3, a β chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4, a β chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 5, and a β chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6.
An isolated or purified protein comprising a first polypeptide chain comprising an α chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1, an α chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 2, and an α chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 3 and a second polypeptide chain comprising a β chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 4, a β chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 5, and a β chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.